Payment overview · 2025
General Payments
$82.35
5 reported records · 5 companies
Healthcare provider profile · identity verified
Olivia Vasquez, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BUNKIE, LA · NPI 1740704238
Verified facts
What the public records show
CMS Open Payments records show Olivia Vasquez, FNP received $82.35 in general payments during 2025 across 5 reported records.
Abbott Laboratories accounted for 24.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.44 | 24.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.71 | 20.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.73 | 19.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.22 | 18.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.25 | 17.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $82.35 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.44 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 177 | 42 |
| Atorvastatin Calcium | Atorvastatin Calcium | 143 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 28 |
| Potassium Chloride | Potassium Chloride | 129 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 128 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 126 | 56 |
| Alprazolam | Alprazolam | 124 | 17 |
| Omeprazole | Omeprazole | 88 | 17 |
| Levothyroxine Sodium | Levothyroxine Sodium | 86 | 18 |
| Metformin Hcl | Metformin Hcl | 85 | 18 |
| Lisinopril | Lisinopril | 84 | 21 |
| Simvastatin | Simvastatin | 78 | 16 |
| Trazodone Hcl | Trazodone Hcl | 71 | 16 |
| Furosemide | Furosemide | 69 | 13 |
| Gabapentin | Gabapentin | 69 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 68 | 15 |
| Losartan Potassium | Losartan Potassium | 66 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 63 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 14 |
| Trulicity | Dulaglutide | 61 | suppressed |
| Azithromycin | Azithromycin | 60 | 46 |
| Naproxen | Naproxen | 60 | 22 |
| Montelukast Sodium | Montelukast Sodium | 59 | 13 |
| Buspirone Hcl | Buspirone Hcl | 55 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 45 | suppressed |
| Famotidine | Famotidine | 44 | suppressed |
| Meloxicam | Meloxicam | 43 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 21 |
| Sertraline Hcl | Sertraline Hcl | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Eliquis | Apixaban | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ofloxacin | Ofloxacin | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | 11 |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $82.35 · 5 records | Abbott Laboratories | BREZTRI, Cologuard Collection Kit, FREESTYLE LIBRE 3, MOUNJARO, XIFAXAN | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error